|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.20 USD | -3.06% |
|
-10.05% | +40.28% |
| 06-29 | Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Index | CI |
| 06-29 | Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell Midcap Growth Benchmark | CI |
| Market Cap | 3.26B 2.86B 2.65B 2.44B 4.61B 312B 4.7B 31.58B 12.39B 153B 12.25B 11.98B 529B | P/E 2026 * |
-7.34x | P/E 2027 * | -43.2x |
|---|---|---|---|---|---|
| Enterprise Value | 2.78B 2.44B 2.26B 2.08B 3.94B 266B 4.01B 26.96B 10.57B 131B 10.45B 10.23B 452B | EV / Sales 2026 * |
3.75x | EV / Sales 2027 * | 2.8x |
| Free-Float |
96.26% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ultragenyx Pharmaceutical Inc.
| 1 day | -3.06% | ||
| 1 week | -10.05% | ||
| Current month | -3.37% | ||
| 1 month | +27.13% | ||
| 3 months | +31.32% | ||
| 6 months | +34.05% | ||
| Current year | +40.28% |
| 1 week | 31.81 |  | 35.79 |
| 1 month | 24.5 | | 36.57 |
| Current year | 18.29 | | 36.57 |
| 1 year | 18.29 | | 39.89 |
| 3 years | 18.29 | | 60.37 |
| 5 years | 18.29 | | 104.38 |
| 10 years | 18.29 | | 179.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
CEO | Chief Executive Officer | 65 | 2010-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 49 | 2023-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | 53 | 2023-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
BRD | Director/Board Member | 65 | 2010-04-21 |
Matthew Fust
BRD | Director/Board Member | 61 | 2013-12-31 |
Michael Narachi
BRD | Director/Board Member | 66 | 2015-02-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-30 | Sell | Chief Financial Officer | -4,698 | 0.0048% | ||
| 06-14 | Sell | Director | -2,000 | 0.0020% | ||
| 06-14 | Sell | General Counsel | -1,899 | 0.0019% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.06% | -10.05% | +10.38% | -26.97% | 3.26B | |
| -3.64% | -8.34% | -5.67% | -83.18% | 1.99B | |
| 0.00% | -2.03% | -12.76% | -16.42% | 310M | |
| -2.11% | -6.83% | -48.67% | - | 50.76M | |
| Average | -2.22% | -1.82% | -14.18% | -42.19% | 1.4B | |
| Weighted average by Cap. | -3.11% | -1.56% | +2.88% | -46.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 741M 650M 602M 554M 1.05B 70.97B 1.07B 7.18B 2.82B 34.85B 2.78B 2.72B 120B | 985M 864M 800M 736M 1.39B 94.28B 1.42B 9.54B 3.74B 46.3B 3.7B 3.62B 160B |
| Net income | -475M -417M -386M -355M -672M -45.5B -685M -4.6B -1.81B -22.34B -1.79B -1.75B -77.17B | -87.97M -77.16M -71.47M -65.76M -124M -8.42B -127M -852M -334M -4.13B -330M -323M -14.28B |
| Net Debt | -478M -419M -388M -357M -675M -45.73B -689M -4.63B -1.81B -22.46B -1.79B -1.75B -77.55B | -508M -446M -413M -380M -719M -48.66B -733M -4.92B -1.93B -23.9B -1.91B -1.87B -82.53B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-14 | US$32.30 | -2.77% | 183,280 |
| 26-07-13 | US$33.22 | -1.77% | 1,394,276 |
| 26-07-10 | US$33.82 | -2.28% | 1,578,134 |
| 26-07-09 | US$34.61 | -0.17% | 1,942,584 |
| 26-07-08 | US$34.67 | -3.35% | 2,775,854 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RARE Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
